Biohaven Ltd. Notes Payable, Noncurrent
Biohaven Ltd. (BHVN) had Notes Payable, Noncurrent of $259.48 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent
us-gaap:LongTermNotesPayable · last filed 2026-08-10
- 2026-06-30: Notes Payable, Noncurrent $259.48M.
- 2026-03-31: Notes Payable, Noncurrent $241.91M.
- 2025-12-31: Notes Payable, Noncurrent $238.90M.
- 2025-09-30: Notes Payable, Noncurrent $268.27M.
| Period end | Notes Payable, Noncurrent |
|---|---|
| 2026-06-30 | $259.48M 10-Q · filed 2026-08-10 |
| 2026-03-31 | $241.91M 10-Q · filed 2026-05-04 |
| 2025-12-31 | $238.90M 10-Q · filed 2026-08-10 |
| 2025-09-30 | $268.27M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $257.07M 10-Q · filed 2025-08-11 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |